



1 En \$

Docket No.: F2842 US S3 (C018016/0180304)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Michael BARDROFF *et al.*) Examiner: G. S. Emch
Serial No.: 10/505,313) Art Unit: 1649
Filed: August 20, 2004)
For: **ANTI-AMYLOID BETA ANTIBODIES**)
AND THEIR USE)

New York, NY
January 13, 2009

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants wish to make of record the following documents (a Form PTO/SB/08 listing the documents is enclosed). The following documents were cited during the prosecution of a Japanese patent application and that of an Israeli patent application corresponding to the above-captioned case.

01/22/2009 SSANDARA 00000022 10505313

01 FC:1806

180.00 OP

FOREIGN PATENT DOCUMENTS

<u>Cite No.</u>	<u>Document No.</u>	<u>Date</u>	<u>Country</u>
1	WO 94/17197	4 Aug. 1994	PCT
2	Hei 03/502455	6 June 1991	Japan


OTHER PUBLICATIONS

- 3 Cheong, et al. "Affinity enhancement of bispecific antibody against two different epitopes in the same antigen," Biochemical and Biophysical Research Communications, 173:795-800 (1990).
- 4 Frenkel, et al. "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," Journal of Neuroimmunology, 95:136-142 (1999).
- 5 Frenkel, et al. "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," Proc. Natl. Acad. Sci., 99:11455-11459 (2000).
- 6 O'Nuallain, et al. "Conformational Abs Recognizing A Generic Amyloid Fibril Epitope," Proc. Natl. Acad. Sci. 99:1485-1490 (2002).
- 7 Solomon, et al. "Disaggregation of Alzheimer β -amyloid by site-directed mAb," Proc. Natl. Acad. Sci., 94:4109-4112 (1997).
- 8 Solomon, et al. "Monoclonal antibodies inhibit *in vitro* fibrillar aggregation of the Alzheimer β -amyloid peptide," Proc. Natl. Acad. Sci. 93:452-455 (1996).
- 9 Schier, et al. "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site" J. Mol. Biol. 263:551-567 (1996).
- 10 Kay, et al. "An M13 Phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets" Gene 128:59-65 (1993).
- 11 Frenkel, et al. "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies" Journal of Neuroimmunology 88: 85-90 (1998).
- 12 Solomon, et al. "Activity of monoclonal antibodies in prevention of *in vitro* aggregation of their antigens" Stability and Stabilization of Biocatalysts 183-188 (1998)


This Third Supplemental Information Disclosure Statement is being filed in accordance with the provisions of 37 C.F.R. § 1.97(c)(2), before the mailing date of any final action, before a notice of allowance, or before an action that otherwise closes prosecution in the application, and is accompanied by the fee set forth in 37 C.F.R. § 1.17(p). Enclosed is a check in the amount of \$180.00 to cover the fee. The Commissioner is authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed. Copies of documents cited are enclosed. Additionally, in accordance with MPEP §609.04(a)(III), an English language version of the abstract of the Japanese Patent Application No. HEI 03/502455 is also enclosed to fulfill the requirement for a concise explanation for non-English language information.

The Examiner's independent consideration of the documents and their relevance before issuance of the next official action is respectfully requested. The Examiner is also requested to initial and return a copy of the accompanying form PTO/SB/08 to evidence such consideration.

If the Examiner has any questions regarding this paper, please contact the undersigned attorney.



Respectfully submitted,


By: 
Jihong Zang
Registration No. 56,606
BRYAN CAVE LLP
1290 Avenue of the Americas
New York, NY 10104-3300
Tel.: (212) 541-2000
Fax: (212) 541-4630

This Third Supplemental Information Disclosure Statement is being filed in accordance with the provisions of 37 C.F.R. § 1.97(c)(2), before the mailing date of any final action, before a notice of allowance, or before an action that otherwise closes prosecution in the application, and is accompanied by the fee set forth in 37 C.F.R. § 1.17(p). Enclosed is a check in the amount of \$180.00 to cover the fee. The Commissioner is authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed. Copies of documents cited are enclosed. Additionally, in accordance with MPEP §609.04(a)(III), an English language version of the abstract of the Japanese Patent Application No. HEI 03/502455 is also enclosed to fulfill the requirement for a concise explanation for non-English language information.


The Examiner's independent consideration of the documents and their relevance before issuance of the next official action is respectfully requested. The Examiner is also requested to initial and return a copy of the accompanying form PTO/SB/08 to evidence such consideration.

If the Examiner has any questions regarding this paper, please contact the undersigned attorney.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 13, 2009.


Jihong Zang, Reg. No. 56,606

Respectfully submitted,

By: 
Jihong Zang
Registration No. 56,606
BRYAN CAVE LLP
1290 Avenue of the Americas
New York, NY 10104-3300
Tel.: (212) 541-2000
Fax: (212) 541-4630